[ET Net News Agency, 16 February 2022] HSBC Global Research lowered its target price
for Sino Biopharm (01177) to HK$9 from HK$9.8 and maintained its "buy" rating.
The research house said Sino Biopharm is its preferred stock in the China pharma space.
(RC)